EUVIMEDEUVIMED entdecken
Crossref

Osteogenic effect of alogliptin in chemical-induced bone loss: a tri-modal in silico , in vitro, and in vivo analysis

Faraha Ahmed, Syed Sufian Ahmad, Mohammad Mumtaz Alam, Mohammad Shaquiquzzaman, Mohammad Altamish, Anuja Krishnan, Divya Vohora, Abul Kalam Najmi iD, Mohammad Ahmed Khan iD

Journal of Pharmacy and Pharmacology · 2025

DOI: 10.1093/jpp/rgae112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Faraha Ahmed und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India. Hauptthemen laut MEDLINE: Uracil, Osteogenesis, Piperidines, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 91 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the effects of Alogliptin in chemical-induced post-menopausal osteoporosis. Methodology The binding affinity of alogliptin with osteogenic proteins was analysed in silico. The effect of alogliptin on osteogenic proteins and mineralization of osteoblastic cells was evaluated in UMR-106 cells. Further, in vivo anti-osteoporotic activity of alogliptin was evaluated in postmenopausal osteoporosis. Various bone turnover markers were assayed in serum. This followed the analysis of microarchitecture of bone, histology, and immunohistochemistry (IHC) of bone tissue.

Results

Docking scores showed that alogliptin has binding affinity for bone alkaline phosphatase (BALP), osteocalcin, and bone morphogenic protein (BMP-2). Alogliptin also enhanced mineralization of osteoblast cells, evidenced with increased ALP, osteocalcin, and BMP-2. Animal studies revealed significant elevation of bone formation markers, bone ALP, osteocalcin and BMP-2, and decreased bone resorption markers, receptor activator of NF-κβ (RANKL), cathepsin K (CTSK), tartrate resistant acid phosphatase (TRAcP5b) in VCD-induced post-menopausal osteoporosis. Micro computed tomography (μCT) analysis and histology of femur bone and lumbar vertebrae demonstrated decrease in trabecular separation and improved bone density. IHC of femur showed reduced DPP4 enzyme.

Conclusions

Alogliptin increased mineralization in osteoblast cells. It had beneficial effects also altered bone turnover markers, repaired the trabecular microstructure, improved bone mineral density, and exhibited bone forming capacity targeting DPP-4 enzyme in postmenopausal osteoporosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UracilOsteogenesisPiperidinesOsteoporosis, PostmenopausalDipeptidyl-Peptidase IV InhibitorsAnimalsFemaleOsteoblastsHumansMolecular Docking SimulationBone RemodelingBone DensityBone Morphogenetic Protein 2OsteocalcinCell LineRatsAlkaline Phosphatase

Stichwörter der Autor:innen

alogliptinbone formationbone resorptionosteogenesispostmenopausal osteoporosis

Substanzen

UracilalogliptinPiperidinesBone Morphogenetic Protein 2OsteocalcinDipeptidyl-Peptidase IV InhibitorsAlkaline Phosphatase

Autor:innen und Institutionen

  • Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
  • Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India.
  • Department of Molecular Medicine, School of Interdisciplinary Science and Technology, Jamia Hamdard, New Delhi 110062, India.

ORCID-Profile: Abul Kalam Najmi, Mohammad Ahmed Khan

Zitieren

APA

Ahmed, F., Ahmad, S. S., Alam, M. M., Shaquiquzzaman, M., Altamish, M., Krishnan, A., Vohora, D., Najmi, A. K., & Khan, M. A. (2025). Osteogenic effect of alogliptin in chemical-induced bone loss: a tri-modal in silico , in vitro, and in vivo analysis. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae112

Vancouver

Ahmed F, Ahmad SS, Alam MM, Shaquiquzzaman M, Altamish M, Krishnan A, et al. Osteogenic effect of alogliptin in chemical-induced bone loss: a tri-modal in silico , in vitro, and in vivo analysis. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgae112

BibTeX
@article{Ahmed2025,
  author = {Ahmed, Faraha and Ahmad, Syed Sufian and Alam, Mohammad Mumtaz and Shaquiquzzaman, Mohammad and Altamish, Mohammad and Krishnan, Anuja and Vohora, Divya and Najmi, Abul Kalam and Khan, Mohammad Ahmed},
  title = {Osteogenic effect of alogliptin in chemical-induced bone loss: a tri-modal in silico , in vitro, and in vivo analysis},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2025},
  doi = {10.1093/jpp/rgae112}
}
Kostenlos starten →